Last reviewed · How we verify
Atracurium, TBW
Atracurium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the neuromuscular junction to produce muscle paralysis.
Atracurium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the neuromuscular junction to produce muscle paralysis. Used for Muscle relaxation during anesthesia for surgical procedures, Facilitation of endotracheal intubation.
At a glance
| Generic name | Atracurium, TBW |
|---|---|
| Sponsor | St. Antonius Hospital |
| Drug class | Non-depolarizing neuromuscular blocking agent |
| Target | Nicotinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Atracurium binds to nicotinic acetylcholine receptors at the motor end plate, preventing acetylcholine from binding and blocking neuromuscular transmission. This results in flaccid paralysis of skeletal muscles. Atracurium is unique in that it undergoes Hofmann elimination (temperature and pH-dependent degradation) and ester hydrolysis, making it suitable for patients with hepatic or renal impairment.
Approved indications
- Muscle relaxation during anesthesia for surgical procedures
- Facilitation of endotracheal intubation
Common side effects
- Histamine release (flushing, hypotension, tachycardia)
- Prolonged neuromuscular blockade
- Anaphylaxis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atracurium, TBW CI brief — competitive landscape report
- Atracurium, TBW updates RSS · CI watch RSS
- St. Antonius Hospital portfolio CI